Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination of spironolactone, an aldosterone receptor antagonist that acts as a potassium-sparing diuretic, and carvedilol, a beta-blocker that also has alpha-1 adrenergic blocking properties. This combination is commonly used in the treatment of heart failure, where spironolactone prevents sodium reabsorption and potassium excretion in the kidney while carvedilol reduces heart rate, blood pressure, and cardiac workload. Clinical evidence from the COPERNICUS study shows that carvedilol remains efficacious when added to background spironolactone therapy in patients with severe heart failure. However, this combination requires careful monitoring of serum potassium levels, blood pressure, and renal function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on spironolactone + carvedilol.